CD163 and neoplasm: We expect that the ongoing prospective study will elucidate the prognostic and predictive significance of IL-8 reflecting the tumor microenvironment with the infiltration of CD163-positive M2 macrophages, and that it will be possible to conduct a clinical trial of an IL-8 inhibitor for high-risk OSCC patients.